TGFbeta1 Effect on Survival of Anticancer Drug - resistant L1210 Sublines / 대한암학회지
Journal of the Korean Cancer Association
;
: 1005-1013, 1998.
Artigo
em Coreano
| WPRIM
| ID: wpr-72156
ABSTRACT
PURPOSE:
The inhibitory effect of TGFbeta1 on survivals of L1210 and anticancer drug- resistant L1210 sublines was investigated and the gene expression of TGFbeta1 in these cells was examined. MATERIALS ANDMETHODS:
The survivals of L1210, adriamycin-resistant(L1210AdR), vincristine-resistant(L1210VcR) or cisplatin-resistant(L1210Cis) cells were measured by MTT assay after treatment of TGFbeta1. Northern analysis was performed for TGFbeta1 gene expression in L1210, L1210AdR, L1210VcR or L1210Cis.RESULTS:
There was no different survival ratio between two groups, control and TGFbeta1(10 ng/ml) treated groups in L1210 cells. However, the survival ratio of L1210AdR was 59% in TGFbeta1 treated group for 96 hours. The survival ratio of L1210VcR was 61% for 96 hours in TGFbeta1 treated group. The survival ratio of L1210Cis was 40% for 96 hours in TGFbeta1 treated group. Expressions of TGFbeta1 gene in drug-resistant sublines were significantly decreased than that of L1210 cells.CONCLUSION:
Growth of anticancer drug-resistant L1210 sublines were inhibited by TGFbeta1 but not in L1210 cells. So, it is suggested that TGFbeta1 gene expression may have a part in anticancer drug-resistance.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Expressão Gênica
/
Grupos Controle
Idioma:
Coreano
Revista:
Journal of the Korean Cancer Association
Ano de publicação:
1998
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS